Philip S. Bernard

20.2k citations

91 papers · 11.2k indexed · 5 hit papers · h-index 36

Cancer Research top 0.1%
Oncology top 0.2%
Molecular Biology top 1%
Pulmonary and Respiratory Medicine top 1%
Genetics top 1%

Co-authors: Charles M. Perou Torsten O. Nielsen Joel S. Parker Matthew J. Ellis Maggie C.U. Cheang Samuel Leung Sherri R. Davies David Voduc
Topics: Breast Cancer Treatment Studies (37 papers)Molecular Biology Techniques and Applications (22 papers)Gene expression and cancer classification (19 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Cell Nature Medicine Nature Genetics
Partner nations: United States Canada Spain

In The Last Decade

Philip S. Bernard

90 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Michael E. Mullins et al. Journal of Clinical Oncology profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. JNCI Journal of the National Cancer Institute profile →
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

2011 699 citations Philip S. Bernard, Mark Ebbert et al. profile →
The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake

1994 569 citations Philip S. Bernard et al. profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Philip S. Bernard

Since Specialization

Citations

This map shows the geographic impact of Philip S. Bernard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip S. Bernard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip S. Bernard more than expected).

Fields of papers citing papers by Philip S. Bernard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip S. Bernard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip S. Bernard. The network helps show where Philip S. Bernard may publish in the future.

Co-authorship network of co-authors of Philip S. Bernard

This figure shows the co-authorship network connecting the top 25 collaborators of Philip S. Bernard. A scholar is included among the top collaborators of Philip S. Bernard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip S. Bernard. Philip S. Bernard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors influencing opioid prescribing after tooth extraction 2022 ·The Journal of the American Dental Association ·Douglas R. Oyler,(unknown),(unknown),Dana Quesinberry,Philip S. Bernard,Hilary L. Surratt,Craig S. Miller	0
2	Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer 2022 ·Communications Biology ·(unknown),(unknown),Andrew Butterfield,Sandra D. Scherer,Emilio Cortes-Sanchez,(unknown),Benjamin T. Spike,Bryan E. Welm,Philip S. Bernard,Thomas A. Zangle	22
3	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer 2019 ·Cancer Research ·Rachel L. Stewart,(unknown),Rachel E. Factor,N. Lynn Henry,Kenneth M. Boucher,Philip S. Bernard,Katherine E. Varley	35
4	Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15 2018 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown),Stacey Knight,Carol Sweeney,Rachel E. Factor,Mohamed E. Salama,Inge J. Stijleman,Venkatesh Rajamanickam,Bryan E. Welm,Sasi Arunachalam,Brandt Jones,(unknown),Kerry Rowe,Melissa H. Cessna,Alun Thomas,Lawrence H. Kushi,Bette J. Caan,Philip S. Bernard,Nicola J. Camp	7
5	Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia 2017 ·Cancer Prevention Research ·Don A. Delker,(unknown),(unknown),N. Jewel Samadder,Wade S. Samowitz,Kajsa E. Affolter,Kenneth M. Boucher,Lisa M. Pappas,Inge J. Stijleman,Priyanka Kanth,Kathryn R. Byrne,Randall W. Burt,Philip S. Bernard,Deborah W. Neklason	14
6	Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer 2017 ·Cancer ·Elizabeth M. Cespedes Feliciano,Marilyn L. Kwan,Lawrence H. Kushi,Wendy Y. Chen,Erin Weltzien,Adrienne Castillo,Carol Sweeney,Philip S. Bernard,Bette J. Caan	39
7	Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies 2016 ·Cancer Research ·Lee W. Jones,Marilyn L. Kwan,Erin Weltzien,Sarat Chandarlapaty,Barbara Sternfeld,Carol Sweeney,Philip S. Bernard,Adrienne Castillo,Laurel A. Habel,Candyce H. Kroenke,Bryan Langholz,(unknown),Chau T. Dang,Britta Weigelt,Lawrence H. Kushi,Bette J. Caan	42
8	Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment 2016 ·PLoS ONE ·James Bradford,Angela Cox,Philip S. Bernard,Nicola J. Camp	19
9	Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics 2014 ·Cancer Epidemiology Biomarkers & Prevention ·Carol Sweeney,Philip S. Bernard,Rachel E. Factor,Marilyn L. Kwan,Laurel A. Habel,Charles P. Quesenberry,(unknown),Erin Weltzien,Inge J. Stijleman,Carole Davis,Mark Ebbert,Adrienne Castillo,Lawrence H. Kushi,Bette J. Caan	94
10	Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens 2013 ·Journal of Molecular Diagnostics ·Matthew D. Wilkerson,(unknown),D. Neil Hayes,Patrick J. Roberts,Roy R. L. Bastien,Michael E. Mullins,Xiaoying Yin,C. Ryan Miller,Leigh B. Thorne,Katherine B. Geiersbach,Kenneth L. Muldrew,William K. Funkhouser,Cheng Fan,Michele C. Hayward,Steven R Bayer,Charles M. Perou,Philip S. Bernard	16
11	A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen 2012 ·Clinical Cancer Research ·Stephen Chia,Vivien Bramwell,Dongsheng Tu,Lois E. Shepherd,Shan Jiang,Tammi L. Vickery,Elaine R. Mardis,Samuel Leung,Karen Ung,Kathleen I. Pritchard,Joel S. Parker,Philip S. Bernard,Charles M. Perou,Matthew J. Ellis,Torsten O. Nielsen	220
12	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial 2012 ·Clinical Cancer Research ·Maggie C.U. Cheang,K. David Voduc,Dongsheng Tu,Shan Jiang,Samuel Leung,Stephen Chia,Lois E. Shepherd,Mark N. Levine,Kathleen I. Pritchard,Sherri R. Davies,Inge J. Stijleman,Carole Davis,Mark Ebbert,Joel S. Parker,Matthew J. Ellis,Philip S. Bernard,Charles M. Perou,Torsten O. Nielsen	105
13	Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation 2012 ·PLoS ONE ·Matthew D. Wilkerson,Xiaoying Yin,Vonn Walter,(unknown),Christopher R. Cabanski,Michele C. Hayward,C. Ryan Miller,Mark A. Socinski,Alden M. Parsons,Leigh B. Thorne,Benjamin E. Haithcock,Nirmal K. Veeramachaneni,William K. Funkhouser,Scott H. Randell,Philip S. Bernard,Charles M. Perou,D. Neil Hayes	192
14	Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types 2010 ·Clinical Cancer Research ·Matthew D. Wilkerson,Xiaoying Yin,Katherine A. Hoadley,Yufeng Liu,Michele C. Hayward,Christopher R. Cabanski,Kenneth L. Muldrew,C. Ryan Miller,Scott H. Randell,Mark A. Socinski,Alden M. Parsons,William K. Funkhouser,Carrie B. Lee,Patrick J. Roberts,Leigh B. Thorne,Philip S. Bernard,Charles M. Perou,D. Neil Hayes	194
15	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancerbreakdown → 2010 ·Clinical Cancer Research ·Torsten O. Nielsen,Joel S. Parker,Samuel Leung,D. Voduc,Mark Ebbert,Tammi L. Vickery,Sherri R. Davies,Jacqueline Snider,Inge J. Stijleman,Jerry P. Reed,Maggie C.U. Cheang,Elaine R. Mardis,Charles M. Perou,Philip S. Bernard,Matthew J. Ellis	542
16	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypesbreakdown → 2009 ·Journal of Clinical Oncology ·Joel S. Parker,Michael E. Mullins,Maggie C.U. Cheang,Samuel Leung,David Voduc,Tammi L. Vickery,Sherri R. Davies,(unknown),Xiaping He,Zhiyuan Hu,John F. Quackenbush,Inge J. Stijleman,Juan Palazzo,J. S. Marron,Andrew B. Nobel,Elaine R. Mardis,Torsten O. Nielsen,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard	3093
17	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancerbreakdown → 2009 ·JNCI Journal of the National Cancer Institute ·Maggie C.U. Cheang,Stephen Chia,David Voduc,Dongxia Gao,Samuel Leung,Jacqueline Snider,Mark Watson,Sherri R. Davies,Philip S. Bernard,Joel S. Parker,Charles M. Perou,Matthew J. Ellis,Torsten O. Nielsen	1641
18	Cytokeratin profiles of male breast cancers 2006 ·Histopathology ·Vincenzo Ciocca,Alessandro Bombonati,Zoran Gatalica,(unknown),(unknown),(unknown),(unknown),(unknown),Federico A. Monzon,Giuseppe Santeusanio,Charles M. Perou,Philip S. Bernard,Juan Palazzo	22
19	Molecular classification of melanoma using real‐time quantitative reverse transcriptase‐polymerase chain reaction 2005 ·Cancer ·Tracey Lewis,John Elder Robison,Roy R. L. Bastien,Brett Milash,Kenneth M. Boucher,Wolfram E. Samlowski,Sancy A. Leachman,R. Dirk Noyes,Carl T. Wittwer,Laurent Perreard,Philip S. Bernard	49
20	Rapid F508del and F508C Assay Using Fluorescent Hybridization Probes 1999 ·Genetic Testing ·Cameron N. Gundry,Philip S. Bernard,Mark G. Herrmann,(unknown),Carl T. Wittwer	39

About Philip S. Bernard

Philip S. Bernard is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 91 papers that have together received 11.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (37 papers), Molecular Biology Techniques and Applications (22 papers) and Gene expression and cancer classification (19 papers). The work is most often cited by research in Cancer Research (5.6k citations), Oncology (5.2k citations) and Molecular Biology (5.0k citations). Philip S. Bernard has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Charles M. Perou, Torsten O. Nielsen, Joel S. Parker, Matthew J. Ellis, Maggie C.U. Cheang, Samuel Leung, Sherri R. Davies, David Voduc, Inge J. Stijleman and Tammi L. Vickery. Their work appears in journals such as Cell, Nature Medicine and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact